Cartesian Therapeutics (1S70) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1S70 Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Cartesian

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1S70 Stock 12 Month Forecast

Average Price Target

€29.69

▲(454.90% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Cartesian Therapeutics in the last 3 months. The average price target is €29.69 with a high forecast of €38.61 and a low forecast of €14.04. The average price target represents a 454.90% change from the last price of €5.35.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","39":"€39","12.75":"€12.75","21.5":"€21.5","30.25":"€30.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38.60780264,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€38.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.687060363333337,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€29.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.03920096,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€14.04</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,12.75,21.5,30.25,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.85,11.13906174153846,13.428123483076924,15.717185224615385,18.006246966153846,20.295308707692307,22.584370449230768,24.87343219076923,27.16249393230769,29.45155567384615,31.740617415384612,34.02967915692307,36.31874089846154,{"y":38.60780264,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.85,10.452850797179487,12.055701594358975,13.658552391538462,15.26140318871795,16.864253985897435,18.467104783076927,20.069955580256412,21.672806377435897,23.275657174615386,24.878507971794875,26.48135876897436,28.084209566153852,{"y":29.687060363333337,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.85,9.249169304615384,9.64833860923077,10.047507913846154,10.446677218461538,10.845846523076922,11.245015827692308,11.644185132307692,12.043354436923078,12.442523741538462,12.841693046153846,13.24086235076923,13.640031655384616,{"y":14.03920096,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.15,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€38.61

Average Price Target€29.69

Lowest Price Target€14.04

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Julian Harrison

BTIG

€38.61

Buy

621.64%

Upside

Reiterated

07/01/26

Cartesian Therapeutics (RNAC) Receives a Rating Update from a Top Analyst

Martin Fan

Wedbush

€33.34

Buy

523.24%

Upside

Reiterated

06/10/26

Wedbush Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)

Gil Blum

Needham

€35.1

Buy

556.04%

Upside

Reiterated

06/09/26

From: , Tuesday, June 9, 2026 1:42 PM 2026 COMPANY FLASH Biotechnology Cartesian Therapeutics, Inc. (RNAC) RATING BUY PRICE TARGET $40.00 PREV CLOSE $5.86 52-WEEK RANGE $5.60 - $15.57 The licensing agreement provides Cartesian access to WestGene's targeted LNP platform. The company initially plans to evaluate the same anti-BCMA CAR mRNA payload currently used in Descartes-08, while retaining the flexibility to advance internally developed next- generation anti-BCMA CAR and TCE constructs into future clinical programs. A China- based Phase I dose-escalation study in patients with generalized myasthenia gravis (gMG) is expected to commence in 2H:26, with initial clinical data anticipated in 1H:27.

Uy Ear

Mizuho Securities

€35.1

Buy

556.04%

Upside

Reiterated

06/09/26

Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (NASDAQ: TNGX), Cartesian Therapeutics (NASDAQ: RNAC) and Abbott Laboratories (NYSE: ABT)

Thomas Smith

Leerink Partners

―

Buy

―

Reiterated

05/27/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Mitchell Kapoor

H.C. Wainwright

€21.94

Buy

310.02%

Upside

Reiterated

05/26/26

H.C. Wainwright Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

05/06/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Kristen Kluska

Cantor Fitzgerald

€14.04

Buy

162.41%

Upside

Reiterated

04/30/26

Cantor Fitzgerald Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Julian Harrison

BTIG

€38.61

Buy

621.64%

Upside

Reiterated

07/01/26

Cartesian Therapeutics (RNAC) Receives a Rating Update from a Top Analyst

Martin Fan

Wedbush

€33.34

Buy

523.24%

Upside

Reiterated

06/10/26

Wedbush Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)

Gil Blum

Needham

€35.1

Buy

556.04%

Upside

Reiterated

06/09/26

Uy Ear

Mizuho Securities

€35.1

Buy

556.04%

Upside

Reiterated

06/09/26

Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (NASDAQ: TNGX), Cartesian Therapeutics (NASDAQ: RNAC) and Abbott Laboratories (NYSE: ABT)

Thomas Smith

Leerink Partners

―

Buy

―

Reiterated

05/27/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Mitchell Kapoor

H.C. Wainwright

€21.94

Buy

310.02%

Upside

Reiterated

05/26/26

H.C. Wainwright Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

05/06/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Kristen Kluska

Cantor Fitzgerald

€14.04

Buy

162.41%

Upside

Reiterated

04/30/26

Cantor Fitzgerald Keeps Their Buy Rating on Cartesian Therapeutics (RNAC)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cartesian Therapeutics

3 Months

Uy EarMizuho Securities

Success Rate

11/25 ratings generated profit

Average Return

-4.65%

Copying Uy Ear's trades and holding each position for 3 Months would result in 44.00% of your transactions generating a profit, with an average return of -4.65% per trade.

1 Year

Gil BlumNeedham

Success Rate

8/24 ratings generated profit

Average Return

-19.74%

Copying Gil Blum's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -19.74% per trade.

2 Years

Gil BlumNeedham

Success Rate

7/24 ratings generated profit

Average Return

-23.93%

Copying Gil Blum's trades and holding each position for 2 Years would result in 29.17% of your transactions generating a profit, with an average return of -23.93% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1S70 Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1S70 has received 13 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 1S70 average Analyst price target in the past 3 months is 29.69.

Each month's total comprises the sum of three months' worth of ratings.

1S70 Financial Forecast

1S70 Earnings Forecast

Next quarter’s earnings estimate for 1S70 is -€0.76 with a range of -€0.91 to -€0.52. The previous quarter’s EPS was -€1.27. 1S70 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 1S70 has Performed in-line its overall industry.

1S70 Sales Forecast

Next quarter’s sales forecast for 1S70 is €155.98K with a range of €0.00 to €433.28K. The previous quarter’s sales results were €67.59K. 1S70 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 1S70 has Performed in-line its overall industry.

1S70 Stock Forecast FAQ

What is DE:1S70’s average 12-month price target, according to analysts?

Based on analyst ratings, Cartesian Therapeutics, Inc.’s 12-month average price target is 29.69.

What is DE:1S70’s upside potential, based on the analysts’ average price target?

Cartesian Therapeutics, Inc. has 454.90% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Cartesian Therapeutics, Inc. a Buy, Sell or Hold?

Cartesian Therapeutics, Inc. has a consensus rating of Strong Buy, which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Cartesian Therapeutics, Inc.’s share price target?

The average share price target for Cartesian Therapeutics, Inc. is 29.69. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €38.61 ,and the lowest forecast is €14.04. The average share price target represents 454.90% Increase from the current price of €5.35.

What do analysts say about Cartesian Therapeutics, Inc.?

Cartesian Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of Cartesian Therapeutics, Inc.?

To buy shares of DE:1S70, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Cartesian Therapeutics (1S70) Stock Forecast & Price Target

1S70 Analyst Ratings

1S70 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cartesian Therapeutics

1S70 Analyst Recommendation Trends

1S70 Financial Forecast

1S70 Earnings Forecast

1S70 Sales Forecast

1S70 Stock Forecast FAQ

Detailed List of Analyst Forecasts